Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Ophthalmology Reports|October 21, 2014
Regenerative Cell Therapy for Corneal EndotheliumAlena Bartakova, Noelia J Kunzevitzky, Jeffrey L Goldberg
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|August 18, 2017
CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinomaAlena Bartakova, Kveta Michalova, Jiri Presl, et al.
Investigative Ophthalmology & Visual Science|April 7, 2018
A Cell Culture Approach to Optimized Human Corneal Endothelial Cell FunctionAlena Bartakova, Olga Kuzmenko, Karen Alvarez-Delfin, et al.
The Journal of Biological Chemistry|May 3, 2014
The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growthJacqueline Sayyah, Alena Bartakova, Nekeisha Nogal, et al.
Investigative Ophthalmology & Visual Science|May 20, 2016
Novel Identity and Functional Markers for Human Corneal Endothelial CellsAlena Bartakova, Karen Alvarez-Delfin, Alejandra D Weisman, et al.
Cancer Medicine|January 24, 2019
Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analysesKarolina Seborova, Radka Vaclavikova, Pavel Soucek, et al.
Journal of Cancer|November 21, 2017
Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal MetastasisKaterina Elsnerova, Alena Bartakova, Josef Tihlarik, et al.
International Journal of Molecular Sciences|October 16, 2024
Microfluidic Affinity Selection of B-Lineage Cells from Peripheral Blood for Minimal Residual Disease Monitoring in Pediatric B-Type Acute Lymphoblastic Leukemia PatientsMalgorzata A Witek, Nicholas E Larkey, Alena Bartakova, et al.
Plos One|May 15, 2015
Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low NeuroblastomaShanique A Young, Katelyn E McCabe, Alena Bartakova, et al.
Oncotarget|September 30, 2015
A strategy to combine pathway-targeted low toxicity drugs in ovarian cancerJoe R Delaney, Chandni Patel, Katelyn E McCabe, et al.
Pageof 2